I never took a position. I had some concerns about the trial hitting both end points and then from a BSTC standpoint I had some specific concerns on how long they would be entitled to EU royalties. Then after seeing Halozyme's program could be applicable in many of the same indications and potentially a much safer product I thought to stay out. Not that I saw the market putting a high value on Xiaflex in either company.
I didn't hear the call yet but saw some twitter posts. It seems there are some concerns about the results and what they have to show for approval.
News 
Market Data 
Discover 
